The systemic immune-inflammation index (SII) predicts neoadjuvant therapy response and survival in patients with pancreatic cancer who are CA 19-9 non-secretors. (2021) - Murthy, P.; Zenati, M.; AlMasri, S.; DeSilva, A.; Bahary, N.; Singhi, A.; Ellsworth, S.; Paniccia, A.; Lee, K.; Lotze, M.; Zureikat, A.